- Home
- VNRX vs ACCS Comparison
VNRX vs ACCS Comparison
Compare VNRX & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNRX
- ACCS
- Stock Information
- Founded
- VNRX N/A
- ACCS 1988
- Country
- VNRX United States
- ACCS United States
- Employees
- VNRX N/A
- ACCS N/A
- Industry
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ACCS Publishing
- Sector
- VNRX Health Care
- ACCS Consumer Discretionary
- Exchange
- VNRX Nasdaq
- ACCS Nasdaq
- Market Cap
- VNRX 52.4M
- ACCS 46.0M
- IPO Year
- VNRX N/A
- ACCS N/A
- Fundamental
- Price
- VNRX $0.80
- ACCS $12.05
- Analyst Decision
- VNRX Strong Buy
- ACCS Strong Buy
- Analyst Count
- VNRX 5
- ACCS 1
- Target Price
- VNRX $3.88
- ACCS $15.00
- AVG Volume (30 Days)
- VNRX 307.1K
- ACCS 8.7K
- Earning Date
- VNRX 08-13-2025
- ACCS 08-07-2025
- Dividend Yield
- VNRX N/A
- ACCS N/A
- EPS Growth
- VNRX N/A
- ACCS N/A
- EPS
- VNRX N/A
- ACCS N/A
- Revenue
- VNRX $1,308,361.00
- ACCS $22,961,000.00
- Revenue This Year
- VNRX $563.72
- ACCS $7.67
- Revenue Next Year
- VNRX $160.43
- ACCS N/A
- P/E Ratio
- VNRX N/A
- ACCS N/A
- Revenue Growth
- VNRX 64.16
- ACCS 6.92
- 52 Week Low
- VNRX $0.40
- ACCS $7.61
- 52 Week High
- VNRX $0.94
- ACCS $13.35
- Technical
- Relative Strength Index (RSI)
- VNRX 75.61
- ACCS N/A
- Support Level
- VNRX $0.40
- ACCS N/A
- Resistance Level
- VNRX $0.75
- ACCS N/A
- Average True Range (ATR)
- VNRX 0.08
- ACCS 0.00
- MACD
- VNRX 0.02
- ACCS 0.00
- Stochastic Oscillator
- VNRX 69.33
- ACCS 0.00
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
About ACCS ACCESS Newswire Inc. Common Stock
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.